

Table 67 Summary of Meiboscore Grading (Safety Set)

Visit	Pro-ocular 0.5% (N=31) n (%)	Pro-ocular 1% (N=30) n (%)	Placebo (N=30) n (%)	Overall (N=91) n (%)
Screening				
0 = No loss of meibomian glands	6 (19.4)	13 (43.3)	6 (20.0)	25 (27.5)
1 = Loss of less than 1/3 of the total meibomian gland area	8 (25.8)	6 (20.0)	3 (10.0)	17 (18.7)
2 = Loss of 1/3 to 2/3 of the total area	13 (41.9)	9 (30.0)	15 (50.0)	37 (40.7)
3 = Loss of more than 2/3 of the area	4 (12.9)	2 (6.7)	6 (20.0)	12 (13.2)
Week 12				
0 = No loss of meibomian glands	6 (25.0)	11 (39.3)	4 (14.8)	21 (26.6)
1 = Loss of less than 1/3 of the total meibomian gland area	11 (45.8)	11 (39.3)	7 (25.9)	29 (36.7)
2 = Loss of 1/3 to 2/3 of the total area	5 (20.8)	6 (21.4)	14 (51.9)	25 (31.6)
3 = Loss of more than 2/3 of the area	2 (8.3)	—	2 (7.4)	4 (5.1)
Missing	2	—	—	2

Source: Table 14.3.5.1.7, Statistical Output in Appendix 16.2.

Table 68 Analysis of Meiboscore Grading (Safety Set)

Week 12	P-value
1% Pro-ocular vs Placebo	0.003
0.5% Pro-ocular vs Placebo	0.105

Source: Table 14.3.5.1.8, Statistical Output in Appendix 16.2.
p-value from Cochran-Mantel-Haenszel test.